Free resources: the Clinical Development Planning hub
The TPP template, estimands playbook and articles on trial design choices that pay off at approval. Free, no pitch.

Fewer than one in ten compounds that enter Phase 1 reach approval. We build the clinical development plan and trial design that put the odds on your side, from preclinical to filing.
A clinical development plan is your comprehensive strategy from first-in-human to submission. We pair our proprietary platforms with senior medical expertise to build it with speed and precision, and to keep every decision pointed at the label you want.
We analyse the early pharmacology, toxicology and safety data to set the trial strategy.
Using InovaLandscape and medical expertise, we pin down the population, disease and outcomes, with live intelligence on prior and ongoing trials.
We choose the endpoints, inclusion and exclusion criteria and sample size, then define what constitutes proof of concept so go/no-go decisions are clear.
We design trials to fit your budget and resources, with strictly no change orders, and track competitor timelines in InovaLandscape.
We identify risks early and build mitigation strategies, strengthened by early adoption of an integrated evidence plan in InoviaIEP.
We bring clinical, regulatory, medical affairs, operations and biostatistics together, so the plan holds up from every angle.

Generate your study schema and schedule of assessments in minutes, then export both straight into your protocol.
The TPP template, estimands playbook and articles on trial design choices that pay off at approval. Free, no pitch.

Every study, endpoint and decision in a strong development plan should trace back to one graded target profile. This is the template we use to build it, so your CDP is designed around the label you actually want.
✓ Grade every attribute from minimal acceptable to best-in-class
✓ Efficacy, safety, dosing, comparator, regulatory and differentiation, with traceable attribute IDs
✓ Built to align to your CDP, so every study earns its place
Why the target label should drive protocol design, and how to work back from it.
Same trial, two right answers: how estimands change what your data means.
Which master-protocol design a single-asset biotech can actually run.

Schedule a meeting with one of our Medical Experts to discuss your CDP and Trial Design